Briefing
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
In 55 people with early breast cancer, ctDNA after curative-intent treatment predicted metastatic relapse, with a median lead time of 7.9 months on serial samples.
- Design: Evidence level 3
- Assay: Not named in the abstract
Science Translational MedicinePubMed 26311728DOI 10.1126/scitranslmed.aab0021